PURPOSE: This study was conducted to assess the suitability of insulin analogs acylated by various cholic acid derivatives for use as basal insulin, and to test the most promising of these, LysB29(Nepsilon-lithocholyl-gamma-Glu) des(B30) human insulin (NN344) in pigs. METHODS: Circular dichroism spectroscopy and size-exclusion chromatography were used to explore the physicochemical properties of the analogs, and affinities for albumin and insulin receptors were determined. After subcutaneous injection in pigs, disappearance half-times were measured, and the plasma profile and glucose-lowering effect in a euglycemic clamp were assessed for NN344. RESULTS: NN344 showed glucose-lowering activity lasting more than 24 h. Glucose infusion rate was essentially constant from 5 to 19 h after injection. NN344 seemed to be a dodecamer in the presence of zinc ions and phenol. Without phenol, the apparent molecular mass was >5000 kDa. Formation of such a self-assembly at the site of s.c. injection and its subsequent slow decomposition might explain the long duration of action of NN344. A measurable affinity for albumin of the lithocholic acid ligand may also contribute to the prolonged action. CONCLUSIONS: NN344 is a candidate for a neutral soluble basal insulin that might offer people with diabetes a prolonged duration, smooth, and predictable basal insulin supplement.
PURPOSE: This study was conducted to assess the suitability of insulin analogs acylated by various cholic acid derivatives for use as basal insulin, and to test the most promising of these, LysB29(Nepsilon-lithocholyl-gamma-Glu) des(B30) humaninsulin (NN344) in pigs. METHODS: Circular dichroism spectroscopy and size-exclusion chromatography were used to explore the physicochemical properties of the analogs, and affinities for albumin and insulin receptors were determined. After subcutaneous injection in pigs, disappearance half-times were measured, and the plasma profile and glucose-lowering effect in a euglycemic clamp were assessed for NN344. RESULTS:NN344 showed glucose-lowering activity lasting more than 24 h. Glucose infusion rate was essentially constant from 5 to 19 h after injection. NN344 seemed to be a dodecamer in the presence of zinc ions and phenol. Without phenol, the apparent molecular mass was >5000 kDa. Formation of such a self-assembly at the site of s.c. injection and its subsequent slow decomposition might explain the long duration of action of NN344. A measurable affinity for albumin of the lithocholic acid ligand may also contribute to the prolonged action. CONCLUSIONS:NN344 is a candidate for a neutral soluble basal insulin that might offer people with diabetes a prolonged duration, smooth, and predictable basal insulin supplement.
Authors: Jean L Whittingham; Ib Jonassen; Svend Havelund; Shirley M Roberts; Eleanor J Dodson; Chandra S Verma; Anthony J Wilkinson; G Guy Dodson Journal: Biochemistry Date: 2004-05-25 Impact factor: 3.162
Authors: J Markussen; S Havelund; P Kurtzhals; A S Andersen; J Halstrøm; E Hasselager; U D Larsen; U Ribel; L Schäffer; K Vad; I Jonassen Journal: Diabetologia Date: 1996-03 Impact factor: 10.122
Authors: Naveed A Bakh; Abel B Cortinas; Michael A Weiss; Robert S Langer; Daniel G Anderson; Zhen Gu; Sanjoy Dutta; Michael S Strano Journal: Nat Chem Date: 2017-09-22 Impact factor: 24.427
Authors: Diana Mikiewicz; Anna Bierczyńska-Krzysik; Agnieszka Sobolewska; Dorota Stadnik; Monika Bogiel; Monika Pawłowska; Anna Wójtowicz-Krawiec; Piotr A Baran; Natalia Łukasiewicz; Agnieszka Romanik-Chruścielewska; Iwona Sokołowska; Jacek Stadnik; Piotr Borowicz; Grażyna Płucienniczak; Andrzej Płucienniczak Journal: PLoS One Date: 2017-03-15 Impact factor: 3.240